Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Merck & Co., Inc. roe for the quarter ending 2026-06-30 was 7.56%, a 77.40% decline year-over-year.
Merck & Co., Inc. roe for the quarter ending 2026-03-31 was 19.45%, a 45.99% decline year-over-year.
Merck & Co., Inc. roe for the quarter ending 2025-12-31 was 34.66%, a 6.09% decline year-over-year.
Merck & Co., Inc. roe for the quarter ending 2025-09-30 was 36.67%, a 34.51% increase year-over-year.
Merck & Co., Inc. roe for fiscal 2025 was 34.66%, a 6.09% decline from fiscal 2024.
Merck & Co., Inc. roe for fiscal 2024 was 36.91%, a 3706.02% increase from fiscal 2023.
Merck & Co., Inc. roe for fiscal 2023 was 0.97%, a 96.92% decline from fiscal 2022.
Merck & Co., Inc. roe for fiscal 2022 was 31.52%, a 7.58% decline from fiscal 2021.